A new medicine which has been nicknamed ‘Viagra for the brain’ could help to slow the onset of Alzheimer’s.
While it has the catchy nickname due to being from the same family as the treatment for erectile dysfunction, the drug’s official name is AR1001.
It also contains mirodenafil, which was created to treat erectile dysfunction but which can also have other uses.
Both Viagra and AR1001 work by blocking PDE5, which is an enzyme in the body that increases blood flow and relaxes blood vessels.
AR1001 is currently in clinical trials, so the research is not conclusive at present, but the latest trial involving 1,535 patients in 13 countries with early onset Alzheimer’s could be promising.
In the study patients were given the AR1001 pill and a control group were given a placebo, with no one person knowing who had which, and researchers then observing patients’ health over the course of a year.
This included monitoring things like how they handled everyday tasks, their memory, and their thinking.
According to developers AriBio, a South Korean company, the daily pill appeared to slow down the decline in 604 people who were not taking any other medication to treat Alzheimer’s.
It said that of that group patients given AR1001 deteriorated 31 percent slower than participants on the placebo.

The study looked at people with early onset Alzheimer’s (Getty Stock)
The results of the trial were shared at the conference for Clinical Trials on Alzheimer’s Disease in Boston in the US.
But despite some indications in patients who were not on other medication, it did not appear to have the same effect on people who were taking other medication.
Researchers also do not currently know exactly why it appeared to achieve those results for people not taking other medication for Alzheimer’s.
Dr Richard Oakley is associate director for research and innovation at Alzheimer’s Society in the UK, and told The Sun: “These topline results are an exciting sign that we could have a totally new treatment for early Alzheimer’s disease that tackles its causes, not just its symptoms.
“AR1001 takes a novel approach, relaxing blood vessels to increase blood flow to the brain.
“And unlike other disease-modifying treatments that have shown benefit in late-stage trials, it is taken as a once-a-day tablet, which could make treatment simpler.

If approved, the medicine could be taken as a daily pill (Getty Stock)
“Over the year of the trial, this drug was able to effectively slow down people’s decline in memory and thinking by nearly a third, and the side effects reported were mostly mild to moderate.
“However, the drug doesn’t seem to be as effective for people taking other drugs for Alzheimer’s symptoms, so this needs further investigation.”
Dr Oakley also clarified that although AR1001 is from the same family as Viagra ‘people should not take Viagra to try to treat Alzheimer’s’.
AR1001 is also not currently publicly available, as it is still in development.
Meanwhile, Dr David Greeley from AriBio said that the findings are ‘very encouraging’, though he acknowledged that ‘further evaluation is needed’.
“If approved, this oral drug would broaden patients’ options,” he said.
Dr Greeley added: “Our goal is meaningful treatment that not only helps patients but that can be realistically afforded, received and sustained.”

Leave a Reply